Korean KFDA IBM
Pharmaceutical Container
GMP Guide

• ▸Resin manufacturer name, HDPE or PP commercial grade designation, lot number
• ▸Certificate of Analysis: MI (g/10min), density (g/cm³), melt point, additive package composition
• ▸Korean KFDA positive list reference or KFDA pharmaceutical contact declaration from resin supplier
• ▸Confirmation: no UV stabilisers, no non-listed slip agents, no prohibited colourants

• ▸All nominal dimensions with tolerances: neck OD, neck bore ID, height, body max OD, fill-mark position
• ▸Volume at fill mark: nominal volume ± tolerance at 23°C
• ▸Container material identification: HDPE or PP, colour, resin identification code
• ▸Revision history and drawing number for version control in Korean KFDA dossier

• ▸Korea Ever-Power machine model (e.g. EP-ZQ80) and unique machine serial number
• ▸Mould set serial number, cavity count, mould material (S136 stainless), cavity-numbering layout diagram
• ▸Production site name and address (Korean IBM container producer’s facility)
• ▸If dual-machine qualification: both serial numbers and both cavity counts documented

Korea Ever-Power produces this report during the pre-delivery production trial at the Korea Ever-Power facility before machine shipment — giving the Korean pharmaceutical brand first-batch dimensional data before the machine arrives at the Korean factory. This pre-delivery report is a unique Korea Ever-Power service that reduces the Korean customer’s on-site qualification timeline by providing validated dimensional data from the first production run.

• ▸30 measurements per dimension per cavity (neck OD, bore ID, height, volume, bottle weight)
• ▸All cavities measured across 3 consecutive production cycles (500 bottle minimum)
• ▸Statistical summary: mean, range, standard deviation per dimension per cavity; Cpk ≥ 1.33 confirmation
• ▸Statement confirming all cavities simultaneously within specification — required for Korean KFDA CTF

Korean Pharmacopoeia plastic container test certificate (Korean accredited laboratory), chemical compatibility study (12 or 24 weeks at 40°C/75% RH using actual pharmaceutical formulation), and closure function test (CRC per KS M ISO 8317, induction seal per ASTM F2096 or dropper cap insertion torque). These three documents are sourced by the Korean pharmaceutical brand or their IBM container supplier, as they require access to the specific pharmaceutical formulation and the specific Korean closure components. Detailed specifications for each test are covered in Sections 4, 5 and 6 of this guide.

Oral Liquid / CRC Medicine (12 weeks)

Total: ~16 weeks from first IBM production sample

Ophthalmic (24 weeks — KFDA requirement)

Total: ~28 weeks from first IBM production sample

STANDARD: KS M ISO 8317

• ▸200 adult test subjects — ≥ 85% open rate within 5 min (adult accessibility criterion)
• ▸200 child test subjects — ≤ 20% open rate within 10 min (child resistance criterion)
• ▸IBM neck OD ±0.05 mm is critical — bead interference within ±0.06 mm window required
• ▸Qualification containers sampled from all cavities in the mould set

STANDARD: ASTM F2096

• ▸Positive pressure bubble test: inflate sealed container to 10 kPa — no bubble emission from seal zone
• ▸IBM neck sealing land flatness ≤ 0.1 mm TIR required for consistent foil bond across all cavities
• ▸100% sample integrity: all containers from all cavities must pass in qualification batch
• ▸Post-distribution simulation: repeat after ISTA 2A conditioning

KOREAN KFDA OPHTHALMIC SPECIFICATION

• ▸Drop volume: 25–35 μl per drop at 23°C from the specific Korean ophthalmic dropper insert
• ▸Dropper cap retention: 10 N axial pull without cap detachment (Korean pharmacist handling test)
• ▸IBM bore ID ±0.04 mm controls drop volume — tested at nominal and tolerance limits
• ▸All cavities tested: 200 containers minimum from each of the 20–30 IBM production cavities

What is the first action a Korean pharmaceutical brand should take when planning a new IBM container qualification?

The first action is to establish the critical path timeline for the qualification project by identifying the route of administration — because the route determines the compatibility study duration that governs the entire qualification timeline. Oral pharmaceutical IBM containers require 12 weeks of accelerated compatibility testing; ophthalmic containers require 24 weeks. The qualification project plan should be built backwards from the required commercial production date, with the compatibility study start date as the fixed anchor. The compatibility study must begin on the day that the first IBM production samples are received from the IBM container producer — not after completing other documentation activities. All other qualification activities (KP testing, dimensional report, closure function testing, CTF compilation) must be planned to complete within the compatibility study window so that the CTF is complete when the compatibility study result is available. Korean pharmaceutical brands that start the compatibility study after completing other activities add 3–6 weeks to the qualification timeline unnecessarily. Korea Ever-Power’s pharmaceutical application team provides a Gantt-format qualification project timeline template to all Korean pharmaceutical IBM customers at the pre-order consultation stage, with the compatibility study as the fixed critical path anchor and all other activities shown as parallel work streams.

What Korean KFDA documentation is required when the HDPE resin supplier changes the additive package within the same grade designation?

A resin supplier’s change to the additive package within the same HDPE commercial grade designation — even if the grade name and MI specification remain unchanged — constitutes a material change for Korean KFDA purposes, because the additive package is part of the resin composition declared in the original container technical file. The correct Korean KFDA treatment depends on the nature of the additive change: if the change is limited to lot-to-lot variation of the same listed antioxidant type and loading (within ±10% of the declared AO quantity) and the resin supplier provides a revised certificate of analysis confirming this, the change may be self-declared as a minor change by the Korean pharmaceutical brand’s QA team. If the additive type changes (e.g. AO-1010 replaced by a different antioxidant), a new antioxidant is added, or the AO loading changes by more than ±10% of the declared amount — this is a major change requiring Korean KFDA notification and typically a new Korean Pharmacopoeia extractables test at minimum, and potentially a new chemical compatibility study if the additive change is assessed to affect the extractable profile in contact with the pharmaceutical formulation. Korean pharmaceutical IBM producers should require their HDPE resin supplier to provide formal written notification of all additive package changes at least 90 days before implementation — sufficient time for the Korean pharmaceutical brand’s QA team to assess the KFDA change classification and initiate the appropriate regulatory action before the new resin lot enters production.

Can Korean KFDA pharmaceutical container qualification be conducted outside Korea — for example, at Korea Ever-Power’s facility in Korea?

The Korean KFDA pharmaceutical container qualification technical file itself can be assembled from data produced at multiple locations — Korea Ever-Power’s dimensional data is produced at its Ansan-si facility in Korea, Korean Pharmacopoeia chemical testing is conducted at a Korean KFDA-accredited laboratory (which may be inside or outside Korea if the laboratory holds relevant Korean KFDA or ICH-recognised accreditation), and the compatibility study is conducted by the Korean pharmaceutical brand at their Korean GMP stability storage facility or at a qualified Korean contract research organisation. The critical requirement is that all testing must use IBM containers produced on the qualified IBM machine at the qualified production site — the production site must be identified in the container technical file, and the Korean KFDA container qualification is specific to that production site. This means that a Korean pharmaceutical brand qualifying an IBM container from a Korean IBM container producer (using a Korea Ever-Power ZQ machine at the Korean producer’s facility) must produce the qualification containers at that Korean IBM producer’s facility — not at Korea Ever-Power’s facility in Ansan-si, unless the Korean pharmaceutical brand’s qualified supplier list includes Korea Ever-Power as a direct primary container manufacturer. Korea Ever-Power’s role in the qualification process is machine supplier — providing the machine, mould set and pre-delivery dimensional documentation — not primary container manufacturer, unless a specific Korean pharmaceutical brand engages Korea Ever-Power directly as their primary container supplier under a separate qualified supplier agreement.

How does Korean KFDA treat IBM container qualification for generic pharmaceutical products entering the Korean market?

Korean KFDA generic pharmaceutical product registration (제네릭 의약품 품목허가) requires the primary container to be qualified as part of the overall product dossier submission. For generic pharmaceuticals targeting the Korean market where an equivalent innovator pharmaceutical product is already registered with a specific primary container (e.g. an ophthalmic product using a 10 ml HDPE IBM container), the generic applicant must submit primary container qualification data that demonstrates bioequivalent container performance — the same container type (HDPE IBM, 10 ml), same closure system (same dropper cap GPI thread), and extractables / leachables data confirming no new or elevated leachable compounds versus the reference listed drug (RLD) container. In practice, Korean generic pharmaceutical applicants do not need to reproduce the full RLD container qualification — they need to demonstrate that their chosen IBM container meets the same Korean KFDA standards as the RLD container, using a qualified Korean IBM container producer and a complete CTF. Korea Ever-Power’s pre-delivery documentation package serves Korean generic pharmaceutical applicants as efficiently as it serves innovator pharmaceutical brands — the cavity-by-cavity dimensional report, machine certification and container drawing are identical in their utility for the Korean KFDA generic product dossier submission as for an innovator NDA submission. Korean generic pharmaceutical projects using Korea Ever-Power IBM containers and the standard GMP documentation package have a typical generic Korean KFDA dossier preparation timeline of 8–14 weeks from first IBM production sample to complete pharmaceutical dossier packaging section, when the compatibility study is the only critical path activity.

What is the correct Korean KFDA approach if one cavity in a 24-cavity IBM mould set produces dimensions outside specification?

If one cavity in a 24-cavity IBM mould set produces dimensions outside the specification in the qualification dimensional report, the qualification cannot proceed until that cavity is brought within specification — because the Korean KFDA pharmaceutical container qualification requires all cavities to be simultaneously within specification, not a statistical sample fraction. The correct sequence is: (1) Identify the out-of-specification cavity by cavity number from the dimensional report. (2) Determine the root cause: hot runner gate imbalance (most common — produces one cavity systematically underweight, with low neck OD), cavity insert dimensional error (requires insert remachining or replacement), or core rod wear at the out-of-specification cavity (requires core rod inspection and replacement if OD is below nominal). (3) Implement corrective action on the specific cavity: gate insert adjustment (for flow imbalance), cavity insert replacement (for dimensional error), or core rod replacement (for wear). (4) Repeat the cavity-by-cavity dimensional qualification run — 500 consecutive production cycles across all 24 cavities — confirming all 24 cavities are simultaneously within specification. (5) Submit the corrected dimensional report as the qualification report. The Korean pharmaceutical brand’s QA team should be notified of the out-of-specification cavity finding and the corrective action taken — this forms part of the qualification deviation management documentation in the Korean GMP quality system. Korea Ever-Power’s mould engineering team provides root cause analysis and corrective action support for out-of-specification cavity findings as a post-delivery service included in the standard pharmaceutical IBM mould warranty.

Does Korean KFDA pharmaceutical container GMP require annual re-qualification or periodic revalidation of the IBM container?

Korean KFDA pharmaceutical container GMP does not require periodic re-qualification of IBM containers that are produced without change — the initial qualification remains valid as long as no change is made to the production equipment (machine, mould), material (resin grade, lot within qualified range), or process conditions (beyond normal process parameter variation within the qualified control range). However, Korean GMP pharmaceutical manufacturers are required to monitor container quality on an ongoing basis through their quality system: cavity-by-cavity container weight monitoring (as a proxy for wall thickness consistency, typically sampled at the start, middle and end of each Korean production batch), periodic neck OD measurement (frequency determined by the pharmaceutical brand’s process capability data — typically every 500,000 cycles for IBM pharmaceutical moulds), and annual container extractables surveillance testing (optional but increasingly expected by Korean pharmaceutical brand QA teams following Korean MFDS GMP inspection guidance updates in 2024). When the IBM mould set approaches the Korea Ever-Power recommended re-polishing interval (500,000 cycles for pharmaceutical moulds) or the core rod replacement interval (typically 2–3 million cycles for pharmaceutical HDPE IBM), the pharmaceutical IBM producer should notify the Korean pharmaceutical brand’s QA team — dimensional monitoring data from the period approaching the maintenance interval should demonstrate that the container remains within qualification specification throughout the pre-maintenance production period, and a post-maintenance first-article dimensional verification run should confirm that dimensions are restored to within specification before resuming commercial production. This maintenance documentation becomes part of the Korean GMP pharmaceutical manufacturer’s change control record — not a Korean KFDA regulatory notification, but an internal quality system document that Korean MFDS GMP inspectors may review during Korean GMP facility inspections.